Hyatt Hotels Corporation vs Medtronic PLC — how do they compare? Hyatt Hotels Corporation trades at $159.3 (market cap $14.81B), while Medtronic PLC trades at $87.8 (market cap $109.38B). The key difference: Medtronic PLC is far larger — about 7.4× Hyatt Hotels Corporation's market cap, and Medtronic PLC pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Medtronic PLC for 63 Days on average.
| H | MDT | |
|---|---|---|
Market Cap | $14.81B | $109.38B |
Volume | 588,239 | 55,890,185 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $105.35 |
52-Week Low | $135.42 | $73.75 |
Typical Hold Time | 148 Days | 63 Days |
Enterprise Value | $18.71B | $128.71B |
Dividend Yield | 0.38% | 3.37% |
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $159.43, up 0.19% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, though Q3 2026 results are pending. Revenue grew to $7.10 billion in 2025, but net income was negative $52 million, reflecting margin pressure. Recent news highlights brand expansion and a strategic loyalty collaboration with Delta Air Lines, signaling growth initiatives amid mixed financial performance.
The outlook for Hyatt is cautiously optimistic, supported by analyst consensus and strategic partnerships, but high valuation multiples and inconsistent profitability pose risks. Upside potential exists if operational improvements and fee growth materialize, yet investors face headwinds from debt levels and competitive pressures in the hospitality sector.
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →